Treatment of Moderate to Severe Glabellar Lines

NCT04249583 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Galderma R&D